NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
CLINICAL TRIALS: MGUS & Smoldering Myeloma




- Dec 10, 2021
NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies


- Dec 1, 2021
The PCROWD Study invites people with precursor conditions to Share samples a few times each year


- Aug 20, 2021
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients


- Jun 26, 2021
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)


- Jun 10, 2021
NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM


- Jun 9, 2021
NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM


- Jun 9, 2021
NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION


- Dec 12, 2020
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis


- Dec 10, 2020
IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test


- Dec 10, 2020
The clonoSEQ® Watch Registry


- Dec 10, 2020
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis


- Jul 1, 2020
NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)


- Dec 14, 2019
NCT04144387: IFM2017 Evaluation of the Impact of the Update SMM Criteria on the Natural History SMM


- Dec 13, 2019
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma


- Dec 12, 2019
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM


- Dec 7, 2019
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma


- Dec 5, 2019
NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy


- Dec 31, 2018
NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population


- Dec 31, 2018
NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM


- Dec 15, 2018
NCT03657251: MMRF CureCloud Research Initiative


- Dec 8, 2018
NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM


- Dec 16, 2017
NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT


- Dec 15, 2017
NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM


- Dec 7, 2017
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM


- Dec 2, 2017
NCT03327597 : Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)


- Dec 30, 2016
NCT02960555: Phase 2 - Isatuximab in Patients With High Risk Smoldering Plasma Cell Myeloma


- Dec 9, 2016
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM


- Dec 9, 2016
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM


- Dec 19, 2015
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial


- Dec 12, 2014
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS


- Dec 11, 2014
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM


- Dec 23, 2012
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma


- Dec 10, 2010
NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06


- Dec 7, 2007
NCT00480363: Phase 3: Revlimid / Dex ( ReDex) VS Observation in Smoldering MM (QUIREDEX)